over 10% SNTS< UP and Away$20-21> Q1 blows out bottom line estimates, doubling what the Street was looking for on higher royalty and licensing payments, plus significant growth in net sales of a number of its key drugs. Total revenues grew 73% Y/Y, boosted by the commercial launch of its colitis drug Ulceris and a big jump in prescriptions written: Glumetza new prescriptions +21%, total prescriptions +18%; Clyoset new prescriptions +21%, total prescriptions +44%. Additionally, sales of Zegerid since its re-launch in February after regaining exclusivity nearly tripled to $24.5M.
Concentrate, and ASK the 8-Ball!